significant differences in the amyloid beta protein, Neprilysin (NEP), and SOX2 levels were not observed among the groups.

**Conclusion:** Our study showed that a single dose of 1X10^6 hUCB-MSCs injected intravenously into AD transgenic mice resulted in neither delivery into the brain nor generation of therapeutic benefits via paracrine activity. In order to utilize the intravenous route as an effective delivery route for AD stem cell therapy, it will be crucial to perform additional studies on how to increase the permeability of the BBB and how to decrease the entrapment of cells in organs such as the lung and liver.

**PT578**

Endothelial-monocyte-activating polypeptide-2 (EMAP-2) may be a novel treatment target of Alzheimer's disease

**Sooh Jang**a,b, Jihyeon Jeongc,d, Eosu Kimc,d, Chul Hoon Kimc,b,d, Kee Namkoonge,c

Department of *Psychiatry and *Pharmacology, *Institute of Behavioral Science in Medicine, *Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea

**Abstract**

Inflammation has been raised as a candidate of unifying pathogenesis and a target of disease modifying strategy for Alzheimer's disease(AD). A cytokine, endothelial-monocyte-activating polypeptide-2 (EMAP-2) which amplifies actions of tumor necrosis factor alpha (TNF-alpha), might be an important target, since it is involved in microglial activation and neuronal death. We hypothesize that EMAP-2 is associated with the Alzheimer’s disease, and anti-EMAP-2 antibody could have therapeutic effects on cognitive impairment in amyloid beta-induced AD model animals.

We investigated the association between the EMAP-2 gene, the -9299A/G polymorphism and cognitive impairment in 641 subjects aged from 60 to 80. In addition, we compared EMAP-2 concentration in peripheral blood among people with AD (n = 30), mild cognitive impairment (n = 29), or normal cognition (n = 27). Finally, we examined the effects of anti-EMAP-2 antibody following injecting it to AD model rats on cognitive function using water maze and passive avoidance tests and on a level of cell death in the brain tissue using TUNEL assay.

We found a significant association between the -9299A/G polymorphism (GG vs AG/AA) of EMAP-2 gene and cognitive impairment. GG homozygote compared to A-allele carriers was related to lower mini-mental status examination score (p = 0.001). In addition, EMAP-2 level was significantly higher in the peripheral blood of people with AD than in that of healthy control group (p = 0.05). In the AD model rats, injection of EMAP-2 antibody improved short-term memory (p < 0.01) and fear memory (p < 0.05), and lowered the levels of neuronal cell death in the brain tissue (p < 0.05).

Our results suggested a possible involvement of EMAP-2 in AD pathogenesis, as well as the potential of humanized anti-EMAP-2 antibody as a novel option for AD treatment.

**PT579**

Disease-modifying therapy through enhancement of neuronal Aβ-degrading enzyme neprilysin activity for Alzheimer's disease

Nobuhisa Iwata, Masashi Asai, Daisuke Hatta, Mikako Honda, Yuma Hori, Momoka Kinoshita, Naotaka Kuroda, Kaname Ohyama, Keiro Shirotani, Takashi Tanaka, Kaoi Watanabe

Nagasaki University, Japan

**Abstract**

Aggregation and deposition of amyloid-ß peptide (Aβ) in the brain are triggering events of the long-term pathological cascade of Alzheimer’s disease (AD), and are closely associated with the metabolic balance between Aβ anabolic and catabolic activities. As almost all familial AD mutations cause an increase in the anabolism of a particular form of Aβ, Aβ1-42, leading to Aβ deposition and accelerating AD pathology, a chronic reduction in the catabolic activity would also promote Aβ deposition. Neprilysin is a rate-limiting peptidease involved in brain Aβ catabolism. Mounting evidence that expression levels of neprilysin are decreased in the hippocampus and cerebral cortex of AD patients from the early stages of disease development and also with aging in humans, suggests a close association of neprilysin with the etiology and pathogenesis of AD. Thus, a subtle but long-term decline in neprilysin activity appears to be at least partly responsible for the memory-related symptoms of AD, and up-regulation of neprilysin would be a promising strategy for disease-modifying therapy of AD.

We screened a compound modulating brain neprilysin activity and/or gene expression using a natural product library, and found that catechins, such as EGCG were capable of up-regulating neprilysin via gene expression. However, their bioavailabilities and blood-brain barrier permeability are not always so good, because these compounds are highly hydrophilic. So, we synthesized aliphatic catechin derivatives by introducing an alkyl chain or aliphatic moiety into EGCG to increase Log P values. Interestingly, some of the aliphatic catechin derivatives more strongly up-regulated not only neprilysin but also α-secretase, which acts to preclude Aβ production, than EGCG did. The aliphatic catechins would be promising drug candidates for therapy and prevention of AD. Currently, we are analyzing their in vivo effects on up-regulation of neprilysin.

**PT580**

Alteration of neuronal nitric oxide synthase dimerization contributes to the development of Alzheimer’s disease

Kyoung Ja Kuwon1, Ryong Eun Kim1, Seung Hwa Park1, Chan Young Shin1, Du-Hyong Cho2,* and Seol-Heui Han1,*

1Department of Neurology, Konkuk University Medical Center and Department of Neuroscience, Center for Geriatric Neuroscience Research, Institute of Biomedical Science and Technology, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143–701, Korea. 2Department of Pharmacology, School of Medicine, Eulji University, 77, Gyeryong-ro, 771 Beon-gil, Jung-gu, Daejeon 301–746, Korea.

**Abstract**

**Background and purpose:** Although previous studies have suggested that nNOS-derived NO has neuroprotective effects on the development of AD, the underlying molecular mechanisms are not fully elucidated. Here, we investigated whether and how disruption of nNOS dimerization contributes to the development of AD.

**Methods:** Two-month-old hemizygous 5xFAD mice and non-transgenic control, and 6-month-old hemizygous 5xFAD mice and non-transgenic control mice were used in the experiments. A histological investigation for neuronal cell death and CDKS/p35 localization, DHE injection for measurement of ROS increase, LT-PAGE for nNOS dimerization/monomerization, and Western blot for CDKS/p35 expression were performed.

**Abstract**

Alteration of neuronal nitric oxide synthase dimerization contributes to the development of Alzheimer’s disease

Kyoung Ja Kuwon1, Ryong Eun Kim1, Seung Hwa Park1, Chan Young Shin1, Du-Hyong Cho2,* and Seol-Heui Han1,*

1Department of Neurology, Konkuk University Medical Center and Department of Neuroscience, Center for Geriatric Neuroscience Research, Institute of Biomedical Science and Technology, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143–701, Korea. 2Department of Pharmacology, School of Medicine, Eulji University, 77, Gyeryong-ro, 771 Beon-gil, Jung-gu, Daejeon 301–746, Korea.
**Results:** No differences in synaptic number or expression of synaptic markers were found in the cortex of 5XFAD mice at 6 months of age compared with control littermates. nNOS dimerization was disrupted in the 5XFAD cortex, accompanied by an increase in ROS production. Furthermore, the levels of p25, a CDK5 activator, increased significantly and it colocalized with nNOS in the 5XFAD cortex.

**Conclusion:** Taken together, our results demonstrate that nNOS dimers are disrupted in the 5xFAD cortex with CDK5 activation, may be involved in the disruption of nNOS dimerization and the development of AD.

**Acknowledgements:** This work was supported by grants from the Ministry of Science, ICT & Future Planning (2013R1A1A2074660) to Seol-Heui Han.

**Keywords:** Alzheimer’s disease, neuronal nitric oxide synthase, dimerization, cyclin-dependent kinase 5, p25

---

**PT581**

Multiple accumulation of neurodegenerative disease-related proteins in familial granulin mutation brains

Masato Hosokawa, Tetsuaki Arai, Hiromi Kondo, Geidy E Serrano, Thomas G Beach, Masato Hasegawa, Haruhiko Akiyama

**Abstract**

Granulin (GRN) mutations were identified in patients with familial frontotemporal lobar degeneration (FTLD) with ubiquitin pathology in 2006 studies. GRN transcript haploinsufficiency has been proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein. GRN mutations were first found in tau-negative FTLD patients, however, recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer’s disease and corticobasal degeneration. Moreover, PGRN reduction in tau transgenic mice is associated with increasing tau phosphorylation and accumulation.

To investigate the influence of a decline in PGRN protein on other forms of neurodegenerative-related protein accumulation, four human GRN mutation cases (age at death; 54, 55, 56 and 78 years old) were investigated by histochemical and biochemical analyses.

The results showed neuronal and glial tau accumulation in all cases analyzed. Massive neuronal tau staining revealed pretangle forms and glial tau in both astrocytes and oligodendrocytes. Furthermore, phosphorylated α-synuclein-positive structures were also found in oligodendrocytes and the neurofilament. Immunoblot analysis of fresh frozen brain tissues revealed that tau protein was present in the Sarkosyl-insoluble fraction, which was composed of three- and four-repeat tau isoforms, resembling Alzheimer’s disease.

Our data suggest that PGRN reduction might be the cause of neuronal and multiple proteinopathies, including TDP-43 proteinopathy, tangleopathy and α-synucleinopathy, due to the accelerating accumulation of abnormal proteins.

---

**PT582**

Myristic Acid Hitchhiking on Sigma-1 Receptor to Fend Off Neurodegeneration

Shang-Yi Tsai, Jenna Ciesielski, Tsung-Ping Su

**Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, Maryland 21224, U.S.A.**

**Abstract**

Neurodegenerative diseases are linked to tangle pathology as a result of cyclin dependent kinase 5 (cdk5) binding to its p25 activator instead of its p35 activator and becoming over-activated. The overactive complex stimulates the hyperphosphorylation of tau proteins, leading to neurofibrillary tangles (NFTs) and stunting axon growth and development. It is known that the sigma-1 receptor (Sig-1R), an endoplasmic reticulum chaperone, is involved in axon growth by promoting neurite sprouting through nerve growth factor (NGF) and tropomyosin receptor kinase B (TrkB). It has also been previously demonstrated that a Sig-1R deficiency impairs the process of neurogenesis by causing a down-regulation of N-methyl-D-aspartate receptors (NMDARs). The study sought to understand the relationship between Sig-1R and tauopathy. It was discovered that the Sig-1R helps maintain proper tau phosphorylation and axon development by facilitating p35 myristoylation and promoting p35 turnover. Neurons that had the Sig-1R knocked down exhibited shortened axons and higher levels of phosphorylated tau proteins compared to control neurons. Here we discuss these recent findings on the role of Sig-1R in tauopathy and highlight the newly presented physiological consequences of the Sig-1R-lipid interaction, helping to understand the close relationship between lipids and neurodegeneration.

---

**PT583**

Long-term Effect of Yokukansankachimpihange on Motivation in wild-type mice

Takuya Hamaguchi1, Iku Tsutsui-Kimura2, Marina Tsukamoto2, Masaru Mimura2, Kenji F. Tanaka2

1Center for Kampo Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan 2Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

**Abstract**

**Backgrounds and Objectives:** Apathy is the loss of motivation, and coincides with 60% of patients with Alzheimer’s disease. The establishment of effective treatments for refractory apathy condition is required. Here we addressed the potentials of treating apathy using Kampo medicine. To pursue this issue, we established the behavioral experiment, which was optimized to the long-term Kampo medication. We examined the long-term (over 6 months) effect of Yokukansankachimpihange (YKSCH), one of the Kampo formulae, on motivation in the instrumental task using wild type mice.

**Methods:** C57BL/6J mice were divided into two groups: YKSCH-containing chow and normal chow was administered. Mice were initially trained to press the lever to earn palatable food reward on a fixed ratio (FR) reinforcement schedule, then trained in a progressive ratio (PR) reinforcement schedule. The final ratio completed represented the break point (BP) and that was recognized as an index of instrumental motivation. YKSCH administration started at the beginning of the FR session. We examined the BP of both group until 40 weeks of age.

**Results:** We first tested whether two sessions per week was enough to maintain the acquired PR performance. Daily PR session was required to evaluate the short-term effect of western medicine, but daily session was laborious in the long-term evaluation of Kampo medication. We optimized the PR task parameter, and confirmed that the modified PR schedule that was conducted twice a week was able to maintain task performance over 6 months.